Shanghai Journal of Stomatology ›› 2023, Vol. 32 ›› Issue (4): 410-416.doi: 10.19439/j.sjos.2023.04.014

• Original Articles • Previous Articles     Next Articles

Effect of metformin combined with DPP-4 inhibitor on alveolar bone density in patients with type 2 diabetes mellitus and chronic periodontitis

LIU Ke1, AHEMAITI Aniwa2,3, TUERNISAGULI Kebier2,3, GULINUER Awut2,3   

  1. 1. Department of Stomatology, Peking University Third Hospital Yanqing Hospital. Beijing102100;
    2. Department of Periodontal, Oral Mucosal Diseases, The First Affiliated Hospital of Stomatology, Xinjiang Medical University. Urumqi830054;
    3. Institute of Stomatology, Xinjiang Uygur Autonomous Region. Urumqi830054, Xinjiang Uygur Autonomous Region, China
  • Received:2022-01-25 Revised:2022-05-08 Published:2023-09-07

Abstract: PURPOSE: To investigate the effect of metformin combined with DPP-4 inhibitor on alveolar bone density in patients with type 2 diabetes mellitus and chronic periodontitis. METHODS: A total of 80 patients with type 2 diabetes mellitus and chronic periodontitis were selected and randomly divided into group A and group B by random number table, with 40 patients in each group. Group A (medication alone group): oral metformin and basic periodontal treatment; Group B (combination group): DPP-4 inhibitor (sitagliptin) was taken orally in addition to group A. Before treatment (T0) and 3 months (T1) and 6 months (T2) after treatment, alveolar bone mineral density (BDM), periodontal probing depth (PD), clinical attachment loss(CAL), probing bleeding (BOP), glycated hemoglobin (HbA1c), serum phosphorus, serum calcium, adiponectin (ADP), leptin (LEP), interleukin-6 (IL-6), C-reactive protein (HS-CRP), tumor necrosis factor (TNF-α) were detected. SPSS 23.0 software package was used for data analysis. RESULTS: Three and 6 months after treatment, PD, CAL, BOP and HbAlc in group B were significantly lower than those in group A(P< 0.05). BDM in group B was significantly higher than that in group A (P< 0.05). Compared with group A, the levels of inflammatory cytokines (IL-6, Hs-CRP, TNF-α) and leptin in group B were significantly decreased, while the level of adiponectin was significantly increased (P< 0.05). CONCLUSIONS: Metformin combined with DPP-4 inhibitor can increase alveolar bone density in patients with type 2 diabetes mellitus and chronic periodontitis, effectively improve periodontal clinical and serum biochemical indicators, and reduce periodontal inflammation.

Key words: Type 2 diabetes mellitus, Periodontitis, Metformin, Adiponectin, DPP-4 inhibitor

CLC Number: